Cannabis
Relay Medical and Swiss PharmaCan AG Announce Initial Glow LifeTech Product Line
Toronto, Ontario–(Newsfile Corp. – April 16, 2020) – Relay Medical Corp. (CSE: RELA) (OTCQB: RYMDF) (FSE: EIY2) (“Relay” or the “Company“), a developer of MedTech innovation, and Swiss PharmaCan AG, an award-winning European bio-tech company, are pleased to provide an update on the Glow LifeTech (“Glow“) Joint-Venture Subsidiary and initial product line.
In early March, Relay Medical announced the signing of an agreement whereby Glow LifeTech Ltd. would acquire the exclusive North American rights for the manufacturing and sales of MyCell InsideTM advanced encapsulation technology (the “Technology”) from Swiss PharmaCan AG for cannabinoids and select nutraceuticals. As Glow, the companies will maintain an ongoing, collaborative working relationship, providing support with ongoing studies, regulatory approvals and access to a pipeline of future product innovations.
“We are ecstatic to bring initial product lines to market in partnership and with the support of the leading-edge operation in Switzerland.” said Yoav Raiter, CEO, Relay Medical Corp. “The technology that will be in our products is of a quality that health-conscious consumers deserve. When you can try it for yourself, and I hope you will, it is undeniably a superior experience.”
“The response to our products and technology has been overwhelming, and we are very excited to continue this success in the largest nutraceutical and cannabis markets in the world through our partnership in Glow Lifetech. This has been a landmark time for our global expansion efforts with the signing of our partnership with MGC Pharmaceuticals in Australia to leverage our technology to develop anti-viral products and our continued roll-out with Relay in North America. ” said Michel Faessler
Initial Product Line
The technology allows Glow to formulate cannabinoids and nutraceuticals with dramatically improved absorption, fast-acting onset, precise dosing and superior health benefits, using all-natural ingredients, to meet the growing demands for next generation value-add products.
Glow LifeTech’s initial focus is to bring the technology’s most popular, natural, and relevant enhanced bio-active vitamins, supplements, and cannabis compounds to the North American marketplace. Glow will offer pure and hybrid products as part of commercialization efforts, subject to relevant legal and regulatory requirements in applicable jurisdictions.
Curcumin
Curcumin is the bioactive substance found in turmeric, which has poor bioavailability on its own and therefore requires special formulations to be properly absorbed1. Modern scientific research has demonstrated its anti-inflammatory, antioxidant, anti-carcinogenic, anti-thrombotic, and cardiovascular protective effects2. Harvard Health, along with many other institutions, sees inflammation at the center of disease management today3. The Curcumin market is set for significant 12.3% CAGR and to exceed $100 million5 in North America by 2025 and with multinational brands like Starbucks Coffee6 already offering infused drinks with curcumin, the market forecast could outperform these expectations.
Immune Boost C-O-C (Curcumin-Olibanum-Vitamin-C)
Vitamin-C is widely known to have immune-boosting properties7, along with tissue repair and supporting collagen formation. The essential oil Olibanum, commonly know as Frankincense, has been found to have cardioprotective benefits8, studied for treatment as an anti-microbial, anti-inflammatory, anti-oxidant and to support liver function.9,10
The powerful combination of Curcumin-Olibanum-Vitamin C is expected to have anti-inflammatory and immune system benefits. The market size for this novel formulation we believe to be substantial and poised for growth amidst cold and flu seasons and the current Covid-19 crisis, as it is imperative that people continue to support their immune systems.
Cannabidiol (CBD) and other Cannabis Products
CBD has been used as a natural pain-reliever derived from the marijuana plant since 2900 B.C11. The legalization has brought to light many other potential benefits for anxiety and pain management.12
The growth and utility of CBD is expansive with a CAGR of over 105%, the U.S. market alone is set to reach $23.7 billion by 202314. Glow LifeTech will navigate the marketplace and offer CBD and THC products to legal jurisdictions and will abide by all local and federal laws surrounding the selling and handling of cannabis-based products.
Iron
Iron therapies and supplementation have been essential in reducing the prevalence of widespread anemia in the population15. Studies show the efficacy for anemia prevention in pregnant women16, who can be at significantly higher risk of developing an iron deficiency17. In addition, iron supplements can support those who take iron-depleting medications prescribed by their doctors.
The Vitamins and Dietary Supplements market size was $37 billion in 2016 and is set to reach $68 billion by 202518. Although iron is only a subset of this marketplace, it has proven to be timeless and essential and is one that will continue to foster strong growth and demand going forward. In partnership with Swiss PharmaCan, Glow will continue product development, research and studies to bring a novel iron supplement to the North American market.
Request a Free Sample
As a celebration of the joint-venture partnership, the Companies are giving 1,000 European consumers the exclusive opportunity to experience a sample of the products ahead of Glow’s North American launch. Interested parties can request a sample at www.glowlifetech.com
About Swiss PharmaCan AG and Micelle Technology AG
Micelle Technology AG, parent company of Swiss PharmaCan is a dynamic organization dedicated to R&D using natural active ingredients (i.e. vitamins and minerals) to improve human health. As one of the leading innovators of plant-based micelle concentrates, Micelle Technology AG offers a unique technology, which enables the company to harness the full potential of herbal active ingredients.
Swiss PharmaCan recently announced the signing of an agreement with MGC Pharmaceuticals Ltd. for necessary research support, commercial manufacturing and distribution of a natural anti-infective based formulation with the aim to treat serious viral infections with inflammatory complications. The Product is based on the Parties’ patented MyCell Enhanced™ delivery system technology.
References:
1 https://examine.com/supplements/curcumin/
2 https://www.ncbi.nlm.nih.gov/pubmed/19233493
3 https://www.health.harvard.edu/newsletter_article/Inflammation_A_unifying_theory_of_disease
4 https://www.ncbi.nlm.nih.gov/pubmed/25945040/
5 https://www.prnewswire.com/news-releases/curcumin-market-size-worth-1-30-billion-by-2025-cagr-12-3-grand-view-research-inc–811278562.html
6 https://athome.starbucks.com/product/starbucks-golden-turmeric/
7 https://www.ncbi.nlm.nih.gov/pubmed/29099763
8https://www.researchgate.net/profile/Ahmed_Zaki49/publication/262608431_Cardioprotective_and_antioxidant_effects_of_oleogum_resin_Olibanum_from_Bos_Boswellia_carteri_Birdw_Bursearceae/links/5a1d67f20f7e9b2a531721f9/Cardioprotective-and-antioxidant-effects-of-oleogum-resin-Olibanum-from-Bos-Boswellia-carteri-Birdw-Bursearceae.pdf
9 https://www.sciencedirect.com/science/article/pii/S1875536414601011
10 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3309643/
11 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549367/
12 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549367/
13 https://www.ncbi.nlm.nih.gov/pubmed/16698671
14 https://www.prnewswire.com/news-releases/us-cbd-market-projected-to-grow-at-107-annual-average-cagr-through-2023-300893763.html
15 https://academic.oup.com/jn/article/132/4/813S/4687233
16 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701721/
17 https://www.ncbi.nlm.nih.gov/pubmed/14601265
18 https://www.grandviewresearch.com/press-release/north-america-dietary-supplements-market-analysis
About Relay Medical Corp.
Relay Medical is a MedTech innovation Company headquartered in Toronto, Canada focused on the development of novel technologies in the diagnostics and data science sectors.
Website: www.relaymedical.com
Contact Information:
Relay Medical Corp.
W. Clark Kent
President
Office. 647-872-9982 ext. 2
TF. 1-844-247-6633 ext. 2
Email: [email protected]
Bernhard Langer
EU Investor Relations
Office. +49 (0) 177 774 2314
Email: [email protected]
Swiss PharmaCan AG and Micelle Technology AG
Mellingerstrasse 10
5443 Niederrohrdorf
Switzerland
Tel: +41 56 508 78 10
Email: [email protected]
Glow LifeTech Ltd.
James Van Staveren
Corporate Development & Research
Glow LifeTech Ltd.
Tel: 647-244-7229
Email: [email protected]
Forward-looking Information Cautionary Statement
Except for statements of historic fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. There are no assurances that the commercialization plans for HemoPalm Corp./UXD Data Sciences Corp. and/or Glow Lifetech Ltd. described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which filings are available at www.sedar.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/54537
TORONTO and GLIL YAM, Israel, Sept. 11, 2024 /PRNewswire/ — IM Cannabis Corp. (“IMC” or the “Company“) (NASDAQ: IMCC) (CSE: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. Shmulik Arbel has been appointed to the Company’s board of directors (the “Board“) effective September 9, 2024. Mr. Arbel brings a wealth of experience in strategic plans that drive profitability, as well as, finance and corporate governance, further strengthening the company’s commitment to driving growth while focusing on sustainable profitability.
“We are thrilled to welcome Shmulik to our Board of Directors,” said Oren Shuster, Chief Executive Officer of IM Cannabis. “Shmulik’s extensive international experience at Leumi, coupled with his proven track record in banking and finance will be invaluable as we continue to deliver on our strategic initiatives.”
Mr. Arbel retired as Deputy CEO from Leumi, Israel’s largest banking group, in April 2023, where he was instrumental in business growth and leading the service revolution. With over 25 years of experience at Leumi, Arbel has held senior roles throughout the organization, such as head of retail banking, head of the corporate division, and as chairman of Leumi UK. With key roles in Israel, New York and London, Mr. Arbel has a wide view on international business.
“I am honored to join the Board of Directors at IMCC,” said Mr. Arbel. “I look forward to leveraging my experience in banking and finance, providing guidance as IMCC continues to establish itself as the go-to brand in the cannabis world. I look forward to contributing to the company’s growth.”
Arbel holds a BA and MBA from Tel Aviv University.
About IM Cannabis Corp.
IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has focused its resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.
The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.
Disclaimer for Forward-Looking Statements
This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, “forward-looking statements“). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to: the stated benefits Mr. Arbel’s appointment, including the further strengthening the Company’s commitment to driving growth in the German market while focusing on sustainable profitability; and Mr. Arbel’s international experience and track record in banking and finance will be invaluable to the Company.
Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the Company’s ability to realize upon the stated benefits Mr. Arbel’s appointment; and Mr. Arbel’s international experience and track record in banking and finance becoming invaluable to the Company.
The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company’s ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and its subsidiaries (collectively, the “Group“) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern Europe and the Middle East, including the impact of the Israel-Hamas war on the Company, its operations and the medical cannabis industry in Israel; risks associated with the Company focusing on the Israel and Germany markets; the inability of the Company to achieve sustainable profitability and/or increase shareholder value; the inability of the Company to actively manage costs and/or improve margins; the inability of the company to grow and/or maintain sales; the inability of the Company to meet its goals and/or strategic plans; the inability of the Company to reduce costs and/or maintain revenues; the Company’s inability to take advantage of the legalization of medicinal cannabis in Germany; and the Company’s inability to realize upon the stated benefits Mr. Arbel’s appointment; and Mr. Arbel’s international experience and track record in banking and finance not becoming valuable to the Company.
Please see the other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual report dated March 28, 2024, which is available on the Company’s issuer profile on SEDAR+ at www.sedarplus.ca and Edgar at www.sec.gov/edgar. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
Company Contact:
Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]
Oren Shuster, CEO
IM Cannabis Corp.
[email protected]
Logo: https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/im-cannabis-announces-appointment-of-shmulik-arbel-to-board-of-directors-302244961.html
Cannabis
Europe Medical Cannabis Market Forecast 2024-2032: Tilray, Aurora Cannabis, and GW Pharmaceuticals Dominate the Market Landscape
Dublin, Aug. 29, 2024 (GLOBE NEWSWIRE) — The “Europe Medical Cannabis Oil Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2024-2032.” report has been added to ResearchAndMarkets.com’s offering.
The Europe Medical Cannabis Oil market is poised for significant growth, projected to escalate from US$ 0.91 billion in 2023 to US$ 2.40 billion by 2032, advancing at a CAGR of 12.08%. In this comprehensive research report, the market is analyzed by:
- Derivatives;
- Source;
- Application;
- Route of Administration;
- End-user;
- Distribution Channel; and
- Country.
Market Highlights Identified in the Report
- Progressive legalization across Europe is creating a favorable regulatory environment, enhancing market expansion for medical cannabis oil products.
- Germany leads the market with a robust infrastructure and supportive regulations, while other countries like the UK, Italy, and Spain show significant growth potential based on evolving regulatory landscapes and market dynamics.
- Key players such as Tilray, Aurora Cannabis Inc., and GW Pharmaceuticals dominate the market, emphasizing research, strategic partnerships, and innovation to maintain competitive edge amidst evolving industry dynamics.
The medical cannabis oil market has experienced substantial growth as legalization and acceptance of cannabis-based treatments expand globally. Cannabis oil, derived from the cannabis plant through extraction methods, contains cannabinoids such as THC and CBD, known for their therapeutic properties. Increasing recognition of cannabis oil’s potential in alleviating symptoms of various medical conditions, including chronic pain, epilepsy, and anxiety disorders, has driven its adoption in medical settings.
Governments in several countries are progressively legalizing medical cannabis, creating a conducive regulatory environment for market expansion. Additionally, growing consumer awareness about alternative and natural therapies has fueled the demand for cannabis oil products. The market is characterized by diverse product offerings, including full-spectrum and CBD-isolate oils, catering to different therapeutic needs and preferences.
Despite regulatory challenges and stigma associated with cannabis, the medical cannabis oil market continues to evolve, driven by ongoing research, favorable legislative changes, and shifting attitudes toward cannabis-based therapies in healthcare.
Regional Insights
Germany is likely to maintain its leadership position in the European medical cannabis oil market due to its established infrastructure, supportive regulations, and strong healthcare system. Germany legalized medical cannabis in 2017, giving the market a head start compared to many other European countries. This established infrastructure and experience position Germany as a leader in the field. As awareness and acceptance of medical cannabis increase, the number of patients seeking treatment in Germany is steadily rising. This fuels market growth and incentivizes further investment in research and development.
Germany’s regulatory framework for medical cannabis is considered relatively patient-friendly compared to some other European countries. This facilitates access for patients with qualifying conditions. The UK legalized medical cannabis in 2018 and is experiencing an increase in patient access programs. This, coupled with ongoing research, could lead to significant market growth. Italy legalized medical cannabis in 2006 but has faced challenges with availability. As regulations become more streamlined and patient access expands, the Italian market holds significant growth potential. Spain has a well-established medical cannabis industry with a focus on domestic production. As regulations evolve and export opportunities increase, the Spanish market could see a boost.
Competitive Landscape
The Medical Cannabis Oil market is characterized by a vigorous competitive landscape, with prominent entities like Tilray, Aurora Cannabis Inc., GW Pharmaceuticals, Almiral, Bedrocan, and others at the forefront, collectively accounting for approximately 41 % of the overall market share. This competitive milieu is fueled by their intensive efforts in research and development as well as strategic partnerships and collaborations, underscoring their commitment to solidifying market presence and diversifying their offerings.
The primary competitive factors include pricing, product caliber, and technological innovation. As the Medical Cannabis Oil industry continues to expand, the competitive fervor among these key players is anticipated to intensify. The impetus for ongoing innovation and alignment with evolving customer preferences and stringent regulations is high. The industry’s fluidity anticipates an uptick in novel innovations and strategic growth tactics from these leading corporations, which in turn propels the sector’s comprehensive growth and transformation.
Key Topics Covered
Chapter 1. Research Framework
Chapter 2. Research Methodology
Chapter 3. Executive Summary: Europe Medical Cannabis Oil Market
Chapter 4. Europe Medical Cannabis Oil Market Overview
Chapter 5. Europe Medical Cannabis Oil Market Analysis, by Derivatives
Chapter 6. Europe Medical Cannabis Oil Market Analysis, by Source
Chapter 7. Europe Medical Cannabis Oil Market Analysis, by Application
Chapter 8. Europe Medical Cannabis Oil Market Analysis, by Route of Administration
Chapter 9. Europe Medical Cannabis Oil Market Analysis, by End-user
Chapter 10. Europe Medical Cannabis Oil Market Analysis, by Distribution Channel
Chapter 11. Europe Medical Cannabis Oil Market Analysis, by Country
Chapter 12. The UK Medical Cannabis Oil Market Analysis
Chapter 13. Germany Medical Cannabis Oil Market Analysis
Chapter 14. The Netherlands Medical Cannabis Oil Market Analysis
Chapter 15. Italy Medical Cannabis Oil Market Analysis
Chapter 16. Spain Medical Cannabis Oil Market Analysis
Chapter 17. Poland Medical Cannabis Oil Market Analysis
Chapter 18. Rest of Europe Medical Cannabis Oil Market Analysis
Chapter 19. Company Profiles (Company Overview, Financial Matrix, Key Product Landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)
A selection of companies mentioned in this report includes, but is not limited to:
- Aurora Cannabis Inc.
- Bedrocan
- Biocann
- BIOTA Biosciences LLC
- Cannamedical
- Mary Jane CBD
- Sanity Group GmbH
- Tilray
- Valcon Medical
For more information about this report visit https://www.researchandmarkets.com/r/dh7q46
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
